Pipeline, products and competition Pharmaceuticals and Vaccines product development pipeline Key In-licence or other alliance relationship with third party Phase I Evaluation of clinical pharmacology, usually conducted in volunteers S Month of first submission Phase II Determination of dose and initial evaluation of efficacy, conducted in a A Month of first regulatory approval for MAA, this is the first EU small number of patients approval letter Phase III Large comparative study compound versus placebo and or established BLA Biological Licence Application treatment in patients to establish clinical benefit and safety MAA Marketing Authorisation Application Europe PO Month of EU Positive Opinion NDA New Drug Application USA MAA and NDA BLA regulatory review milestones shown in the table below are those that have been achieved.
Future filing dates are not included in this list.
Achieved regulatory review milestones Compound Type Indication Phase MAA NDA BLA Respiratory 2126458 phosphoinositide 3 kinase inhibitor idiopathic pulmonary fibrosis I 2256294 soluble epoxide hydrolase inhibitor COPD I 2269557 phosphoinositide 3 kinase inhibitor asthma & COPD I 2793660 cathepsin C inhibitor bronchiectasis I 2862277 tumour necrosis factor receptor-1 domain antibody acute lung injury I danirixin 1325756 CXCR2 chemokine receptor antagonist COPD I fluticasone furoate glucocorticoid agonist long-acting beta2 agonist COPD I vilanterol muscarinic acetylcholine antagonist umeclidinium 961081 muscarinic acetylcholine antagonist, beta2 agonist COPD II 2245035 toll-like receptor 7 agonist asthma II 2339345 sodium channel blocker cough II 2586881 recombinant human angiotensin converting enzyme 2 acute lung injury II fluticasone furoate glucocorticoid agonist muscarinic acetylcholine asthma II umeclidinium antagonist losmapimod p38 kinase inhibitor oral COPD also acute coronary syndrome II mepolizumab IL5 monoclonal antibody nasal polyposis II mepolizumab IL5 monoclonal antibody severe asthma also eosinophilic granulomatosis III with polyangiitis Relvar Breo Ellipta long-acting beta2 agonist glucocorticoid agonist COPD mortality outcomes III vilanterol fluticasone furoate vilanterol long-acting beta2 agonist COPD III fluticasone furoate glucocorticoid agonist asthma Submitted S: Oct13 Incruse Ellipta muscarinic acetylcholine antagonist COPD also hyperhidrosis Submitted PO: Feb14 S: Apr13 umeclidinium Anoro Ellipta muscarinic acetylcholine antagonist long-acting COPD Approved PO: Feb14 A: Dec13 umeclidinium beta2 agonist vilanterol Relvar Breo Ellipta long-acting beta2 agonist glucocorticoid agonist asthma Approved A: Nov13 vilanterol fluticasone furoate Relvar Breo Ellipta long-acting beta2 agonist glucocorticoid agonist COPD Approved A: Nov13 A:May13 vilanterol fluticasone furoate Paediatric Vaccines RSV recombinant respiratory syncytial virus prophylaxis I maternal immunisation RSV recombinant viral vector respiratory syncytial virus prophylaxis I S. pneumoniae next recombinant conjugated Streptococcus pneumoniae disease prophylaxis II generation MMR live attenuated measles, mumps, rubella prophylaxis III US A: Nov 97 Mosquirix recombinant malaria prophylaxis Plasmodium falciparum III N A Malaria RTS, S Nimenrix conjugated Neisseria meningitis groups A, C, W & Y Approved A: Apr12 MenACWY-TT disease prophylaxis II, US Other Vaccines HIV recombinant HIV disease prophylaxis I NTHi recombinant non-typeable Haemophilus influenzae prophylaxis I Hepatitis C recombinant viral vector hepatitis C virus prophylaxis II HIV recombinant HIV disease immunotherapy II Tuberculosis recombinant tuberculosis prophylaxis II Zoster recombinant Herpes Zoster prophylaxis III Flu prepandemic H5N1 inactivated split monovalent Quebec pre-pandemic & pandemic influenza prophylaxis Approved N A A: Nov13 Flu vaccine inactivated split quadrivalent seasonal influenza prophylaxis Approved A: Feb13 A: Dec12 The use of the brand name is not approved by any regulatory authorities GSK Annual Report 2013 225 Investor information Pipeline, products and competition Pharmaceuticals and Vaccines product development pipeline continued Achieved regulatory review milestones Compound Type Indication Phase MAA NDA BLA Antigen-Specific Cancer Immunotherapeutic PRAME recombinant treatment of resectable non-small cell lung cancer II immunotherapeutic MAGE-A3 recombinant treatment of bladder cancer II immunotherapeutic WT1 immunotherapeutic recombinant treatment of breast cancer II MAGE-A3 recombinant treatment of melanoma III immunotherapeutic MAGE-A3 recombinant treatment of non-small cell lung cancer III immunotherapeutic HIV ViiV Healthcare 1265744 HIV integrase inhibitor long-acting HIV infections II parenteral formulation dolutegravir abacavir HIV integrase inhibitor reverse HIV infections - fixed dose combination Submitted S:Oct13 S:Oct13 sulphate lamivudine transcriptase inhibitors fixed dose combination Tivicay dolutegravir HIV integrase inhibitor HIV infections Approved A: Jan14 A: Aug13 Oncology 525762 bromodomain inhibitor NUT gene midline carcinoma I 2141795 trametinib AKT protein kinase inhibitor cancer I MEK1 2 inhibitor 2256098 focal adhesion kinase inhibitor cancer I 2636771 phosphatidylinositol 3-kinase inhibitor cancer I 2849330 ErbB3 monoclonal antibody cancer I 3052230 fibroblast growth factor ligand trap cancer I afuresertib 2110183 AKT protein kinase inhibitor multiple myeloma I Votrient pazopanib multi-kinase angiogenesis inhibitor renal cell cancer I MK-3475 PD-1 monoclonal antibody afuresertib 2110183 AKT protein kinase inhibitor ovarian cancer II foretinib  transition factor non-small cell lung cancer II C-met kinase inhibitor Mekinist trametinib MEK1 2 inhibitor BRAF protein kinase colorectal cancer II Tafinlar dabrafenib inhibitor human anti-EGFR panitumumab monoclonal antibody Revolade Promacta thrombopoietin receptor agonist acute myeloid leukaemia II eltrombopag Revolade Promacta thrombopoietin receptor agonist aplastic anaemia II eltrombopag Revolade Promacta thrombopoietin receptor agonist myelodysplastic syndromes II eltrombopag Tafinlar dabrafenib BRAF protein kinase inhibitor non-small cell lung cancer II Arzerra ofatumumab CD20 human monoclonal antibody chronic lymphocytic leukaemia, use in relapsed patients III Arzerra ofatumumab CD20 human monoclonal antibody diffuse large B cell lymphoma relapsed patients III Arzerra ofatumumab CD20 human monoclonal antibody follicular lymphoma refractory & relapsed patients III Mekinist trametinib MEK1 2 inhibitor BRAF protein kinase metastatic melanoma, adjuvant therapy III Tafinlar dabrafenib inhibitor Tyverb Tykerb lapatinib human epidermal growth factor receptor-2 breast cancer, neo-adjuvant & adjuvant therapy III Her2 and epidermal growth factor receptor EGFR dual kinase inhibitor Votrient pazopanib multi-kinase angiogenesis inhibitor renal cell cancer, adjuvant therapy III Arzerra ofatumumab CD20 human monoclonal antibody chronic lymphocytic leukaemia, first line therapy Submitted S: Oct13 S: Oct13 Votrient pazopanib multi-kinase angiogenesis inhibitor ovarian cancer, maintenance therapy Submitted S: Aug13 Mekinist trametinib MEK1 2 inhibitor metastatic melanoma Approved S: Feb13 A: May13 Mekinist trametinib MEK1 2 inhibitor BRAF protein kinase metastatic melanoma Approved S: Feb13 A:Jan14 Tafinlar dabrafenib inhibitor Revolade Promacta thrombopoietin receptor agonist hepatitis C induced thrombocytopaenia Approved A: Sep13 A: Nov12 eltrombopag Tafinlar dabrafenib BRAF protein kinase inhibitor metastatic melanoma Approved A:Aug13 A:May13 Tyverb Tykerb lapatinib Her2 and EGFR dual kinase inhibitor metastatic breast cancer, in combination with trastuzumab Approved A: Jul13 226 GSK Annual Report 2013 Pharmaceuticals and Vaccines product development pipeline continued Achieved regulatory review milestones Compound Type Indication Phase MAA NDA BLA Cardiovascular & Metabolic 1278863 prolyl hydroxylase inhibitor topical wound healing I 2881078 selective androgen receptor modulator heart failure I 1278863 prolyl hydroxylase inhibitor anaemia associated with chronic renal disease II & peri-operative risk reduction 2330672 ileal bile acid transport inhibitor type 2 diabetes II camicinal motilin receptor agonist delayed gastric emptying II losmapimod p38 kinase inhibitor acute coronary syndrome also COPD II retosiban oxytocin antagonist threatened pre-term labour II darapladib Lp-PLA2 inhibitor atherosclerosis also diabetic macular oedema III Eperzan albiglutide GLP 1 agonist type 2 diabetes Submitted PO: Jan14 S: Jan13 Immuno-inflammation 2586184 Janus kinase 1 JAK1 inhibitor ulcerative colitis I 2618960 IL7 receptor monoclonal antibody autoimmune disease I 3117391 macrophage targeted histone deacetylase rheumatoid arthritis I inhibitor 2586184 Janus kinase 1 JAK1 inhibitor systemic lupus erythematosus also psoriasis II 3196165 MOR103 granulocyte macrophage colonyrheumatoid arthritis II stimulating factor monoclonal antibody belimumab B lymphocyte stimulator monoclonal transplant rejection also myaesthenia gravis II antibody i. v. Benlysta belimumab B lymphocyte stimulator monoclonal systemic lupus erythematosus III antibody s. c. Benlysta belimumab B lymphocyte stimulator monoclonal vasculitis III antibody i. v. sirukumab IL6 human monoclonal antibody s. c. rheumatoid arthritis III Rare Diseases 2398852 SAP monoclonal antibody amyloidosis I 2696274 ex-vivo stem cell gene therapy metachromatic leukodystrophy II 2696275 ex-vivo stem cell gene therapy Wiscott-Aldrich syndrome II ozanezumab neurite outgrowth inhibitor NOGO-A amyotrophic lateral sclerosis II monoclonal antibody 2696273 ex-vivo stem cell gene therapy adenosine deaminase severe combined immune III deficiency ADA-SCID mepolizumab IL5 monoclonal antibody s. c. eosinophilic granulomatosis with polyangiitis III also severe asthma Volibris ambrisentan endothelin A antagonist chronic thromboembolic pulmonary hypertension III Infectious Diseases 2838232 antiviral maturation inhibitor HIV infections I 2878175 NS5B polymerase inhibitor hepatitis C I 1322322 polypeptide deformylase inhibitor bacterial infections II 2140944 type 2 topoisomerase inhibitor bacterial infections II tafenoquine 8-aminoquinoline Plasmodium vivax malaria II Relenza i. v. zanamivir neuraminidase inhibitor i. v. influenza III Neurosciences 2647544 Lp-PLA2 inhibitor Alzheimer's disease I 239512 H3 receptor antagonist multiple sclerosis II 249320 myelin-associated glycoprotein monoclonal stroke II antibody belimumab B lymphocyte stimulator monoclonal myaesthenia gravis also transplant rejection II antibody i. v. ofatumumab CD20 human monoclonal antibody s. c. multiple sclerosis also pemphigus vulgaris II rilapladib Lp-PLA2 inhibitor Alzheimer's disease II GSK Annual Report 2013 227 Investor information Pipeline, products and competition Pharmaceuticals and Vaccines product development pipeline continued Achieved regulatory review milestones Compound Type Indication Phase MAA NDA BLA Ophthalmology 933776 beta amyloid monoclonal antibody geographic retinal atrophy II darapladib Lp-PLA2 inhibitor diabetic macular oedema also atherosclerosis II Dermatology 1940029 stearoyl CoA desaturase 1 inhibitor topical acne vulgaris I umeclidinium muscarinic acetylcholine antagonist topical hyperhidrosis also COPD I 2586184 Janus kinase 1 JAK1 inhibitor psoriasis also lupus II 2894512 non-steroidal anti-inflammatory atopic dermatitis & psoriasis II ofatumumab CD20 human monoclonal antibody s. c. pemphigus vulgaris also multiple sclerosis II Toctino alitretinoin retinoic acid receptor modulator chronic hand eczema III N A Duac low dose clindamycin benzoyl peroxide gel acne vulgaris Approved A: Mar13 N A Brand names appearing in italics are trademarks either owned by and or licensed to GlaxoSmithKline or associated companies.
Option-based alliances with third parties that include assets in phase I and phase II development: Company Disease Area Phase Cancer Research UK cancer I Dynavax Technologies cutaneous & systemic lupus erythematosus II ISIS Pharmaceuticals  amyloidosis II III hepatitis B I OncoMed Pharmaceuticals oncology I II Shionogi bacterial infection I Two assets 228 GSK Annual Report 2013 Pharmaceutical products, competition and intellectual property Major Patent expiry dates Products Compounds Indication s competitor brands USA EU Respiratory 2025 2025 Anoro Ellipta umeclidinium bromide COPD Spiriva, Onbrez NCE NCE vilanterol terfenatate 2016-2029 2016-2029 device device 1 Avamys Veramyst fluticasone furoate rhinitis Nasonex 2021 2023 Flixotide Flovent fluticasone propionate asthma COPD Qvar, Singulair 2016 expired Diskus device Diskus device 2013-2025 2017 HFA-device HFA-device formulation formulation Relvar Breo fluticasone furoate asthma COPD Symbicort, Foster, 2022 2022 Ellipta vilanterol terfenatate US COPD only Flutiform, Dulera NCE NCE 2016-2029 2016-2029 device device Seretide Advair salmeterol xinafoate asthma COPD Symbicort, Foster, 2016 expired fluticasone propionate Flutiform, Dulera Diskus device Diskus device 2013-2025 2017 HFA-device HFA-device formulation formulation Serevent salmeterol xinafoate asthma COPD Foradil, Spiriva, 2016 expired Onbrez Diskus device Diskus device 2019 HFA-device formulation Ventolin HFA albuterol sulphate asthma COPD generic companies 2015-2025 2012-2017 HFA-device HFA-device formulation formulation Anti-virals Relenza zanamivir influenza Tamiflu expired 2014 Valtrex valaciclovir genital herpes, coldsores, Famvir expired expired shingles Zeffix Epivir-HBV lamivudine chronic hepatitis B Hepsera 2014 expired use use Central nervous system Lamictal lamotrigine epilepsy, bipolar disorder Keppra, Dilantin expired expired Imigran Imitrex sumatriptan migraine Zomig, Maxalt, Relpax expired expired Requip XL ropinirole Parkinsons disease Mirapex expired expired Seroxat Paxil paroxetine depression, various Effexor, Cymbalta, expired expired anxiety disorders Lexapro Cardiovascular and urogenital 1 Avodart dutasteride benign prostatic hyperplasia Proscar, Flomax, 2015 2017 finasteride Coreg CR carvedilol phosphate mild-to-severe heart failure, Toprol XL 2016 NA hypertension, left ventricular formulation dysfunction post MI Lovaza omega-3 acid ethyl esters very high triglycerides Tricor expired NA See Risk factors on page 233 for details of uncertainty on the timing of follow-on competition.
1 See Note 44 to the financial statements, Legal proceedings.
GSK Annual Report 2013 229 Investor information Pipeline, products and competition Pharmaceutical products, competition and intellectual property continued Major Patent expiry dates Products Compounds Indication s competitor brands USA EU Anti-bacterials Augmentin amoxicillin clavulanate common bacterial generic products NA expired potassium infections Oncology Arzerra ofatumumab refractory chronic MabThera Rituxan, 2030 2023 lymphocytic leukaemia Imbruvica Mekinist trametinib metastatic melanoma Yervoy, Zelboraf 2025 NA Promacta eltrombopag idiopathic thrombocytopenic Nplate, 2022 2025 Revolade purpura, Hepatitis C MabThera Rituxan associated thrombocytopenia Tafinlar dabrafenib mesylate metastatic melanoma Yervoy, Zelboraf 2030 not yet granted Tykerb Tyverb lapatanib advanced and metastatic Herceptin, 2020 2023 breast cancer in HER2 Kadcyla positive patients Votrient pazopanib soft tissue sarcoma Yondelis, Sutent, 2023 2025 metastatic renal cell Nexavar, Afinitor carcinoma Rare diseases Volibris ambrisentan pulmonary hypertension Tracleer, Revatio NA 2020 Immuno-inflammation Benlysta belimumab systemic lupus erythematosus 2023 2021 Vaccines Boostrix diphtheria, tetanus, acellular booster vaccination Adacel 2017 2017 pertussis Infanrix Pediarix diphtheria, tetanus, pertussis, diphtheria, tetanus, pertussis, Pentacel, Pediacel, 2017 2014 polio, hepatitis B, polio, hepatitis B Pentaxim, Pentavac, Haemophilus influenzae Haemophilus influenzae Hexaxim type B type B Cervarix HPV 16 & 18 virus like human papilloma virus Gardasil Silgard 2020 2020 particles VLPs, AS04 type 16 and 18 adjuvant MPL aluminium hydroxide Fluarix split inactivated influenza seasonal influenza Vaxigrip, Mutagrip, 2022 2022 virus subtypes A and Fluzone, Influvac, subtype B antigens Aggripal, Fluad, Intenza, Flumist Fluarix Tetra split inactivated influenza seasonal influenza Intenza, Flumist QIV, 2022 2022 virus subtypes A and Vaxigrip QIV, subtype B antigens Fluzone QIV, Fluzone High Dose FluLaval split inactivated influenza seasonal influenza Vaxigrip, Mutagrip, none none virus subtypes A and Fluzone, Influvac, subtype B antigens Aggripal, Fluad, Intenza, Flumist Pandemrix derived split inactivated A H1N1 v2009 influenza Focetria, Celvapan, 2014 2014 influenza virus antigen, prophylaxis AS03 adjuvant Prepandrix derived split inactivated pandemic H5N1 Aflunov, Vepacel 2014 2014 influenza virus antigen, influenza prophylaxis AS03 adjuvant Synflorix conjugated pneumococcal invasive pneumococcal Prevenar Prevnar NA 2021 polysaccharide disease, pneumonia acute otitis media 230 GSK Annual Report 2013
